Why This Ovarian Cancer Drug Could Be Huge for NewLink Genetics

Health and Healthcare

Published: December 24, 2019 9:40 am

NewLink Genetics Corp. (NASDAQ: NLNK) shares jumped on Tuesday after the company announced that it entered into an exclusive worldwide license agreement with Ellipses Pharma.

The agreement is for the development of and rights to commercialize NLG207 for the treatment of ovarian cancer.

Under the terms of the agreement, Ellipses purchased NewLink’s inventory of NLG207 related materials, and NewLink will have the potential to receive future royalty payments or a share of any future economics related to NLG207.

As part of the license agreement, Ellipses also gained the rights to develop and commercialize CRLX-301, a nanoparticle formulation of docetaxel that has completed a Phase 1a study.

Dr. Rajan Jethwa, CEO and founder of Ellipses, commented:

We are excited to have reached an agreement with NewLink on a worldwide license for NLG207. Our Scientific Affairs Group confirmed that this compound has shown some encouraging signs in Phase 2 trials and has the potential to improve the standard of care for patients with ovarian cancer that recurs after initial treatment. Our dedicated clinical trials team is eager to rapidly progress the development of this compound for patients suffering from a devastating disease and who currently have relatively few treatment options.

Shares of NewLink traded up about 15% at $2.25 early Tuesday, in a 52-week range of $1.13 to $2.37. The consensus price target is $4.00.

24/7 Wall St.
The Top Biopharma Calendar Events to Watch Going Into 2020

In 20 Years, I Haven’t Seen A Cash Back Card This Good

After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.

A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.

Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.